Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation

NCT01719536 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT01719536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01719536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation
Lead sponsor
Betta Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2012
Completion date
February 7, 2017
Enrollment
296 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc